



## CASE AND RESEARCH LETTER

[Translated article] Low Clinical Relevance of Positive Patch Test Reactions to Limonene and/or Linalool Hydroperoxides in 247 Consecutive Patients with Eczema

**Escasa relevancia clínica en los parches positivos a limoneno y/o linalool en 247 pacientes consecutivos con eccema**

*To the Editor,*

Hydroperoxides of limonene and linalool are found in common fragrances in half of all cosmetic products and household items out there. Also, they can be found in some foods in certain studies.<sup>1,2</sup> Their most frequent use is as a food additive, in perfumes, and in cosmetics, and their oxidation products, especially furanoids, pyranoids, and hydroxyperoxides, increase their sensitizing capacity.<sup>3</sup> (Fig. 1).

The frequency of positive patch tests to both hydroperoxides in some series of patients with contact dermatitis is high,<sup>2,4-6</sup> but their relevance has been poorly studied.

Therefore, we patch-tested 247 consecutive patients with suspected contact dermatitis at Hospital de la Princesa, Madrid, Spain from 2019 through 2021, using the standard series from the Spanish Contact Dermatitis and Allergy Research Working Group (GEIDAC), to which we additionally added 0.5% and 1% limonene hydroperoxide, and 0.1% and 0.3% linalool hydroperoxide (Chemotechnique Diagnostics, Vellinge, Sweden). These allergens were prepared at the time to avoid oxidation. Readings obtained on days D2 and D4 in full compliance with the ESCD guidelines.<sup>7</sup>

Clinical information was collected before performing the patch tests. The application of a product containing terpene in the area affected by the eczema and its resolution upon discontinuing this drug was established as relevant in patients with positive patch tests.



A total of 21 out of the 247 patients tested (8.1%) showed positivity to, at least, 1 of the 2 hydroperoxides in some of the concentrations tested, 7 (2.8%) to limonene hydroperoxide, 14 (5.6%) to linalool hydroperoxide, and 3 (1.2%) to both.

Demographic and clinical data, as well as the results from the patch tests (negative or positive, regardless of intensity), are shown in **Table 1**.

The mean age of patients who tested positive to both terpenes was 57 years (range, 29-81 years). A total of 66% of the patients were women, and none had an occupational origin. The most frequently affected eczema ravaged regions were the hands (in 42% of our cases).

Only in 1 patient (4.7%) the hydroperoxides coexisting with concurrent contact sensitization to FM I and FM II were considered relevant. The remaining positive patches to linalool and/or limonene—a total of 6 (28.6%)—were irritative, not relevant, or of unknown relevance.

In 20 out of 21 patients, other positive reactions were found in the patch tests. The most common one, considered relevant, were 8 positive cases for nickel sulfate, with current or past relevance in 6 cases; 4 positive cases for methylchloroisothiazolinone/methylisothiazolinone (MCI/MI); 3 for FM I or II, and another 3 for paraphenylenediamine (PPD)/textile dye mixture. The diagnoses of patients with positive patches to hydroperoxides varied and included atopic dermatitis, allergic contact and irritant eczemas, and psoriasis, as seen in [Table 1](#).


In this series of patients who were patch tested with limonene and linalool hydroperoxides with suspected contact dermatitis, most positive patches were irrelevant. In most patients, atopic dermatitis and irritant contact dermatitis explained the clinical lesions. In fact, in cases of contact dermatitis, other allergens from the standard series were involved.

The clinical relevance of hydroxyperoxides in the studies conducted varies widely, ranging from 29% to 97% of the cases reported.<sup>4-6</sup> In the GEIDAC prospective series, it was considered that 50% of the patients had clinical relevance, with a prevalence of positive reactions in 5.1% of the patients.<sup>3</sup> Nonetheless, the criteria used for relevance are classical, and they do not take the clinical course into consideration. In contrast, in our series, only 4.7% of the positive reactions reported were relevant, and these results are consistent with those reported by Natsch et al.<sup>8</sup>

DOI of original article:  
<https://doi.org/10.1016/j.ad.2023.05.035>

<https://doi.org/10.1016/j.ad.2024.01.014>

0001-7310/© 2024 Published by Elsevier España, S.L.U. on behalf of AEDV. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



**Figure 1** Formulas of linalool and limonene, IUPAC name, and the main products where they can be present.

**Table 1** Clinical and epidemiological characteristics of tested patients.

Sex/age	Hatopy	Loc	Epic limonene	Rel. limonene	Epic linalool	Rel. linalool	Rem. epic	Rel. other	Final diagnosis
M/75	No	Folds	POS	NR	NEG		Hydrocortisone/ Budesonide	CPR	ACD to corticoids
M/44	No	T/Folds	POS	CPR	POS	CPR	Fragance m I/II	CPR	ACD to perfume
W/77	No	T/A	NEG	—	POS	IR	None	—	Psoriasis
M/74	No	A	NEG	—	POS	IR	Epoxy resin/ benzisothiazolinone	NR/IR	Phytophotodermatitis
W/55	Yes	H	NEG	—	POS	IR	MCI/MI, LL	CPR	ACD/ICD/Atopic d
W/81	No	F	POS	IR	POS	IR	Ni	IR	Hiperpigmentation
M/70	No	Sp	POS	UR	POS	UR	MCI/MI	CPR	ACD to preservatives
W/72	No	H	NEG	—	POS	NR	Ni	PPR	ICD
W/67	Yes	Sp	NEG	—	POS	NR	Phenoxyethanol/Ni/ Benzisothiazolinone	CPR/PPR/IR	Atopic d
W/33	Yes	Feet	NEG	—	POS	NR	Formaldehyde 2%/Quaternium imidozolidinylurea/	PR/PR/PR	Atopic d
W/46	Yes	Folds	NEG	—	POS	NR	Ni	PR	Atopic d
M/37	Yes	H	POS	NR	POS	NR	Black rubber/Cobalt/ Textile dye mixture/ Thiomersal	IR	Atopic d
W/29	Yes	F	NEG		POS	IR	Ni/LL	IR	Atopic d
W/47	Yes	S/T	POS	NR	NEG		PPD/Textile dye mixture	CPR	ACD PPD
W/60	No	S	NEG	—	POS	NR	PPD/Textile dye mixture/NI	CPR/PPR	ACD PPD

**Table 1** (Continued)

Sex/age	Hatopy	Loc	Epic limonene	Rel. limonene	Epic linalool	Rel. linalool	Rem. epic	Rel. other	Final diagnosis
W/28	Yes	Sp	NEG	—	POS	UR	MCI/MI; M fragancies I, II	CPR/CPR	ACD to preservatives/fragrances
W/49	Yes	Sp	NEG	—	POS	UR	Ni	PPR	Atopic d
M/60	Yes	H	NEG	—	POS	NR	Fragance m I/Compositae	CPR/UR	ACD and Atopic d
W/76	No	F	NEG	—	POS	UR	Sodium gold thiosulfate	IR	Cuperosis
M/81	Yes	LL	POS	UR	NEG		Ni	PPR	ICD
W/37	No	Sp	NEG	—	POS	UR	Ni	PPR	Cuperosis

A, arms; ACD, allergic contact dermatitis; Atopic d, atopic dermatitis; CPR, current positive relevance; Epic, epicutaneous; F, face; Fragance m, fragrance mix; H, hands; Hatopy, history of atopy; ICD: irritant contact dermatitis; IR, irritative; LL, lower limbs; loc, location of the lesion; M, man; MCI/MI: Methylchloroisothiazolinone/methylisothiazolinone; NEG, negative; Ni, nickel; NR, non-relevant; POS, positive; PPD: paraphenylenediamine; PPR, past positive relevance; PR, past relevance; Rel., relevance; Rem. epic, remaining epicutaneous tests (only the positive ones shown); S, scalp; Sp, spread; T, trunk; UR, unknown relevance; W, woman.

However, we agree with the authors of other series with high prevalences like ours, who also mentioned that the allocation of clinical relevance to these positive reactions is poorly documented and that criteria need to be standardized on this regard.<sup>9</sup> Also, that patients with atopic dermatitis may show irritative reading patterns which may be different from those of the overall population.<sup>10</sup>

In our experience, the clinical relevance of both hydroperoxides is very low, meaning that exposure sources need to be thoroughly investigated before considering their inclusion in the standard series in Spain.

## Conflicts of interest

M. Llamas-Velasco: participation in clinical trials, lectures, research support, and advisory boards of Abbvie, Amgen, Almirall, Boehringer, Brystol-Meyers, Celgene, Leo, Lilly, Janssen-Cilag, Novartis, and UCB.

J. Sánchez Pérez: research support, and participation in clinical trials for Abbvie, Almirall, Galderma, Leo, and Boehringer.

The remaining authors declared no conflicts of interest whatsoever.

None of the conflicts of interest reported are associated with the information provided in this article.

## References

1. Bennike N, Oturai N, Müller S, Kirkeb CS, Jørgensen C, Christensen AB, et al. Fragrance contact allergens in 5588 cosmetic products identified through a novel smartphone application. *J Eur Acad Dermatol Venereol.* 2018;32:79–85.
2. Ogueta IA, Bråred Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, et al. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. *Contact Dermatitis.* 2022;87:1–12.
3. Deza LG, García-Bravo B, Silvestre JF, Pastor-Nieto MA, González-Pérez R, Heras-Mendaza F, et al. Contact sensitiza-

tion to limonene and linalool hydroperoxides in Spain: A GEIDAC\* prospective study. *Contact Dermatitis.* 2017;76:74–80.

4. Bråred Christensson J, Hellén S, Börje A, Karlberg AT. Limonene hydroperoxide analogues show specific patch test reactions. *Contact Dermatitis.* 2014;70:291–9.
5. Dittmar D, Schuttelaar ML. Contact sensitization to hydroperoxides of limonene and linalool: Results of consecutive patch testing and clinical relevance. *Contact Dermatitis.* 2019;80:101–9.
6. Bennike NH, Zachariae C, Johansen JD. Non-mix fragrances are top sensitizers in consecutive dermatitis patients — a cross-sectional study of the 26 EU-labelled fragrance allergens. *Contact Dermatitis.* 2017;77:270–9.
7. Johansen JD, Aalto-Korte K, Agner T, Andersen KE, Bircher A, Bruze M, et al. European Society of Contact Dermatitis guideline for diagnostic patch testing—recommendations on best practice. *Contact Dermatitis.* 2015;73:195–221.
8. Natsch A, Nägelin M, Leijs H, Van Strien M, Giménez-Arnau E, Very M, et al. Exposure source for skin sensitizing hydroperoxides of limonene and linalool remains elusive: An analytical market surveillance. *Food Chem Toxicol.* 2019;127:156–62.
9. Ramzi A, Ahmadi H, Sadiktsis I, Nilsson U. A two-dimensional non-comprehensive reversed/normal phase high-performance liquid chromatography/tandem mass spectrometry system for determination of limonene and linalool hydroperoxides. *J Chromatogr A.* 2018;1566:102–10.
10. Chen JK, Jacob SE, Nedostost ST, Hanifin JM, Simpson EL, Boguniewicz M, et al. A pragmatic approach to patch testing atop dermatitis patients: Clinical recommendations based on expert consensus opinion. *Dermatitis.* 2016;27:186–92.

M. Llamas-Velasco<sup>a,b,\*</sup>, L. Martos-Cabrera<sup>b</sup>, B. Butrón<sup>b</sup>, J. Sánchez-Pérez<sup>a,b</sup>

<sup>a</sup> Instituto de Investigación Sanitaria Princesa (IP), Madrid, España

<sup>b</sup> Departamento de Dermatología, Hospital Universitario de la Princesa, Madrid, España

\*Corresponding author.

E-mail address: mar.llamasvelasco@gmail.com (M. Llamas-Velasco).